NEW YORK, December 21 /PRNewswire/ -- Paul Capital Healthcare today announced that it has led an investment to provide more than US$100 million to UCB S.A. in exchange for certain payments relating to the sales of products marketed by third parties. The underlying third party products (which are non-core to UCB) are leading brands in their therapeutic fields.
This transaction underscores Paul Capital Healthcare's continued ability to help innovative companies access transformative growth capital, said Dr. Ken Macleod in Paul Capital Healthcare's London office. These are quality products that have the support of strong marketing partners. We believe that this transaction will provide benefit to both Paul Capital Healthcare and UCB.
As evidenced by this investment, Paul Capital Healthcare is committed to working with companies to tailor transactions that meet their near-term financial needs and long-term growth objectives, said Andrew Rubinstein in Paul Capital Healthcare's New York office. Our approach is an attractive alternative to traditional equity and debt financing for a variety of pharmaceutical, biotechnology and medical device companies in the United States, Europe and Asia, including major global pharmaceutical companies such as UCB.
About Paul Capital Healthcare and Paul Capital
Through its funds, Paul Capital Healthcare is one of the largest dedicated healthcare investors globally, with more than US$1.6 billion in equity capital commitments and debt facilities under management. Combined, the Paul Capital Healthcare funds have invested more than US$1 billion in the pharmaceutical, biotechnology, and medical device sectors. These investments are focused on commercial stage companies and products, and consist of investments in the form of royalties, revenue interests, debt and equity. Additional information on Paul Capital Healthcare can be found at www.paulcapitalhealthcare.com. Paul Capital Partners manages nearly US$7.3 billion in capital commitments for its three investment platforms, which include Paul Capital Healthcare, Private Equity Secondary Funds and Top Tier Fund-of-Funds. The firm has offices in New York, San Francisco, Paris, London, Hong Kong, and Sao Paolo.
SOURCE: Paul Capital Healthcare
CONTACT: Susan Rood, +1-212-843-0210, srood@lazarpartners.com; orStephanie Seiler, +1-206-713-0124, sseiler@lazarpartners.com, both of PaulCapital Healthcare; or Ken Macleod, Ph.D., Partner of Paul CapitalHealthcare, +44-20-7514 0754, kmacleod@paulcap.com
Comments